Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
Johnson & Johnson’s worldwide year-over-year sales declined 10.8% in the second quarter of 2020, as fewer consumers had elective surgery or opted to buy beauty products during the pandemic.
The company’s medical device segment dropped 33.9% to $4.3 billion, while its consumer health division, which includes skin care brands Neutrogena and Aveeno, fell 7% to $3.3 billion. The New Jersey-based healthcare products manufacturer noted, however, that sales of Tylenol and Listerine mouthwash were strong, helping to mitigate the overall loss.
J&J’s
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in